OpenAI’s ChatGPT exploded onto the scene in November 2022, attracting 1 million users in 5 days, and now more than 1.5 billion visits per month. It joins the class of AI tools including several used in computational chemistry and drug discovery that the biotechnology industry has been implementing for years, including IPOs of AI-based biotechs. This session will examine the present business cases for which AI applications are showing greatest reliability of returns across the drug development process and which are still too early in the hype cycle.